EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Menno Pruijm, Nicolas Belmar, Petter Bjornstad, David Z I Cherney, Vivek Das, Thomas Gunnarsson, Jeffrey B Hodgin, Philip A Schytz, Katherine R Tuttle, Matthias Kretzler

Kidney International · 2026-01 · 109 (1) · 6-16

DOI: 10.1016/j.kint.2025.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2026-01. Verfasst von Menno Pruijm und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service of Nephrology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland. Electronic address: menno.pruijm@chuv.ch. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Novo Nordisk AS, Doris Duke Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease poses a major global health burden and is one of the most common complications of type 2 diabetes. Drug trials have demonstrated that treatments, including sodium-glucose cotransporter-2 inhibitors, a glucagon-like peptide-1 receptor agonist, and a nonsteroidal mineralocorticoid receptor antagonist, mitigate chronic kidney disease progression, but the underlying nephroprotective mechanisms of action remain incompletely understood, partly ascribed to their pleiotropic actions. New innovative trial designs are needed to tackle simultaneously the hemodynamic and structural effects induced by these drugs. The REMODEL trial (REnal MODE of action of semagLutide in patients with type 2 diabetes and chronic kidney disease; ClinicalTrials.gov identifier: NCT04865770) is designed to explore the mechanisms of action of semaglutide with a novel multiparametric approach, integrating functional magnetic resonance imaging and research kidney biopsies for structural and molecular interrogation and blood and urine biomarker analysis. Better understanding of these mechanisms will help explain semaglutide's beneficial effects on kidney disease outcomes, reported in the FLOW (Evaluate Renal Function with Semaglutide Once Weekly; ClinicalTrials.gov identifier: NCT03819153) trial, and may identify patient subpopulations to optimize treatment strategies. By combining diverse and state-of-the-art methods, REMODEL aims to pave the way to a larger use of mechanism of action trials in the near future. To this purpose, this article describes the REMODEL framework, methods, technical challenges, and lessons learned as a platform for future mechanistic trials of chronic kidney disease therapies and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesGlucagon-Like PeptidesHypoglycemic AgentsKidneyRenal Insufficiency, ChronicHumansBiomarkersBiopsyDisease ProgressionMagnetic Resonance ImagingMulticenter Studies as TopicClinical Trials, Phase III as TopicGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

chronic kidney diseaseclinical trialstype 2 diabetes

Substanzen

BiomarkersGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Service of Nephrology, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland. Electronic address: menno.pruijm@chuv.ch.
  • Global Medical Affairs, Product and Portfolio Strategy, Novo Nordisk A/S, Søborg, Denmark.
  • Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington Medicine Diabetes Institute, Seattle, Washington, USA; Department of Pediatrics, Division of Endocrinology, Universit…
  • Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
  • Clinical Omics Science, Data Science, Research & Development, Novo Nordisk A/S, Søborg, Denmark.
  • Department of Pathology and Clinical Laboratories, University of Michigan, Ann Arbor, Michigan, USA.

Förderung

  • National Institutes of Health
  • Novo Nordisk AS
  • Doris Duke Charitable Foundation
  • Juvenile Diabetes Research Foundation Canada
  • Bayer

Zitieren

APA

Pruijm, M., Belmar, N., Bjornstad, P., Cherney, D. Z. I., Das, V., Gunnarsson, T., Hodgin, J. B., Schytz, P. A., Tuttle, K. R., & Kretzler, M. (2026). REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney International, 109(1), 6-16. https://doi.org/10.1016/j.kint.2025.10.005

Vancouver

Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, et al. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney International. 2026;109(1):6-16. doi:10.1016/j.kint.2025.10.005

BibTeX
@article{Pruijm2026,
  author = {Pruijm, Menno and Belmar, Nicolas and Bjornstad, Petter and Cherney, David Z I and Das, Vivek and Gunnarsson, Thomas and Hodgin, Jeffrey B and Schytz, Philip A and Tuttle, Katherine R and Kretzler, Matthias},
  title = {REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide},
  journal = {Kidney International},
  year = {2026},
  volume = {109},
  number = {1},
  pages = {6--16},
  doi = {10.1016/j.kint.2025.10.005}
}
Kostenlos starten →